Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUSTS trial of trabectedin infusion schedules versus doxorubicin in untreated advanced soft tissue sarcoma
NL-OMON35987Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trabectedin and doxorubicin in soft tissue sarcoma (STS) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-free survival and Treatment safety. Started Sep 2011; status: active, not recruiting.
02
Drugs
trabectedindoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON35987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35987.